The impact of demographic, clinical, genetic, and imaging variables on tau PET status

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Purpose: A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) are tau PET–negative, while some clinically diagnosed non-AD neurodegenerative disorder (non-AD) patients or cognitively unimpaired (CU) subjects are tau PET–positive. We investigated which demographic, clinical, genetic, and imaging variables contributed to tau PET status. Methods: We included 2338 participants (430 Aβ+ AD dementia, 381 Aβ+ MCI, 370 non-AD, and 1157 CU) who underwent [18F]flortaucipir (n = 1944) or [18F]RO948 (n = 719) PET. Tau PET positivity was determined in the entorhinal cortex, temporal meta-ROI, and Braak V-VI regions using previously established cutoffs. We performed bivariate binary logistic regression models with tau PET status (positive/negative) as dependent variable and age, sex, APOEε4, Aβ status (only in CU and non-AD analyses), MMSE, global white matter hyperintensities (WMH), and AD-signature cortical thickness as predictors. Additionally, we performed multivariable binary logistic regression models to account for all other predictors in the same model. Results: Tau PET positivity in the temporal meta-ROI was 88.6% for AD dementia, 46.5% for MCI, 9.5% for non-AD, and 6.1% for CU. Among Aβ+ participants with AD dementia and MCI, lower age, MMSE score, and AD-signature cortical thickness showed the strongest associations with tau PET positivity. In non-AD and CU participants, presence of Aβ was the strongest predictor of a positive tau PET scan. Conclusion: We identified several demographic, clinical, and neurobiological factors that are important to explain the variance in tau PET retention observed across the AD pathological continuum, non-AD neurodegenerative disorders, and cognitively unimpaired persons.

Detaljer

Författare
  • Hanna Cho
  • Carole H. Sudre
  • Tomas Olsson
  • Erik Stormrud
  • Young Hoon Ryu
  • Jae Yong Choi
  • Adam L. Boxer
  • Maria L. Gorno-Tempini
  • Bruce L. Miller
  • David Soleimani-Meigooni
  • Leonardo Iaccarino
  • Renaud La Joie
  • Edilio Borroni
  • Gregory Klein
  • Michael J. Pontecorvo
  • Michael D. Devous
  • Sylvia Villeneuve
  • Chul Hyoung Lyoo
  • Gil D. Rabinovici
Enheter & grupper
Externa organisationer
  • VU University Medical Center
  • Severance Hospital
  • King's College London
  • University College London
  • Skåne University Hospital
  • Korea Institute of Radiological & Medical Sciences (KIRAMS)
  • University of California, San Francisco
  • F. Hoffmann-La Roche AG
  • Avid Radiopharmaceuticals, Inc
  • Lawrence Berkeley National Laboratory
  • Vrije Universiteit Amsterdam
  • Yonsei University
  • Lund University
  • McGill University
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi
  • Neurovetenskaper

Nyckelord

Originalspråkengelska
Sidor (från-till)2245-2258
Antal sidor14
TidskriftEuropean Journal of Nuclear Medicine and Molecular Imaging
Volym48
Utgåva nummer7
Tidigt onlinedatum2020 nov 19
StatusPublished - 2021 jul 1
PublikationskategoriForskning
Peer review utfördJa